May 2014 | Targeted Therapies in Oncology

Early-Stage Lung Cancer: Refining Treatment Plans

August 26, 2014

Clinical Articles

The optimal management of patients with early-stage NSCLC remains controversial, and the prospect of exposing an otherwise low-risk patient to potentially toxic chemotherapy based on limited prognostic information remains a problem for many clinicians.

Aligning High Science With Health Care

August 08, 2014

Clinical Articles

New and evolving strategies for clinical trial design are under way, a point that was made abundantly clear April 25th at the NCCN Policy Summit on Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies.

A New Concept to Broaden Access to Molecular Testing

August 06, 2014

Clinical Articles

During a 2013 discussion on treating NSCLC, a group of oncologists were asked what share of cancer patients have access to molecular testing. The answers varied: One said he guessed 40% to 50%, another said "a large minority."

Veliparib Shows Responses in Ovarian Cancer

June 23, 2014

Clinical Articles

Major objective responses to treatment were demonstrated in one-fourth of patients with relapsed or refractory BRCA-mutant ovarian cancer with the investigational PARP inhibitor, veliparib, according to results from a phase II study.